<i>EGFR</i>m NSCLC: Global Insights
Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

Released: March 25, 2021

Expiration: March 24, 2022

Enriqueta Felip
Enriqueta Felip, MD
Matthew Gubens
Matthew Gubens, MD, MS

Activity

Progress
1
Course Completed

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:

  • Biomarker testing and strategies
  • Optimal first-line therapy in patients with NSCLC
  • Management of patients with CNS disease
  • Selecting therapy for patients with noncanonical mutations
  • Management strategies after progression on first-line EGFR TKI therapy
  • Selecting therapy for patients with early stage disease

Presenters: 

Enriqueta Felip, MD, PhD
Head, Thoracic Oncology Unit
Oncology Service
Vall dHebron University Hospital
Barcelona, Spain

Matthew Gubens, MD, MS
Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California